RAPT — Rapt Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $276.66m
- $117.80m
- 30
- 20
- 15
- 10
Annual income statement for Rapt Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 5.04 | 3.81 | 1.53 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 43.6 | 58.3 | 73 | 87.3 | 127 |
| Operating Profit | -43.6 | -53.2 | -69.2 | -85.8 | -127 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.3 | -51.9 | -69.2 | -83.8 | -117 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -43 | -52.9 | -69.2 | -83.8 | -117 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -43 | -52.9 | -69.2 | -83.8 | -117 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43 | -52.9 | -69.2 | -83.8 | -117 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.89 | -2.19 | -2.53 | -2.58 | -3.05 |